Cerenis Therapeutics Holding SA (CEREN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cerenis Therapeutics Holding SA (CEREN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7995
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as patients with HDL deficiency, and post-ACS patients. It also develops drugs that increase HDL for patients with low number of HDL particles to treat atherosclerosis and related metabolic diseases. Cerenis works in partnership with other research and biotechnology companies for the development of HDL drug delivery products and technologies. The company has presence in France and the US. Cerenis is headquartered in Labege, France.

Cerenis Therapeutics Holding SA (CEREN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cerenis Therapeutics Holding SA, Medical Devices Deals, 2012 to YTD 2018 9
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Cerenis Therapeutics Acquires Assets from Lypro Biosciences 11
Venture Financing 12
Cerenis Therapeutics Raises USD4.1 Million in Venture Financing 12
Partnerships 13
Cerenis Therapeutics Enters into University of North Texas Health Science Center 13
Equity Offering 14
Cerenis Therapeutics to Raise USD1.3 Million in Private Placement of Shares 14
Cerenis Therapeutics Raises USD56.7 Million in IPO 15
Asset Transactions 17
Cerenis Therapeutics Acquires Assets from Lypro Biosciences 17
Cerenis Therapeutics Holding SA – Key Competitors 18
Cerenis Therapeutics Holding SA – Key Employees 19
Cerenis Therapeutics Holding SA – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Sep 10, 2018: Cerenis Therapeutics announces 2018 half-year results 21
Jul 18, 2018: Cerenis Therapeutics: Cash position and activity update for H1 2018 and key perspectives for the end of 2018 22
Feb 01, 2018: Cerenis Therapeutics: 2017 Annual Results And Update On Tango 23
Jul 20, 2017: Cerenis Therapeutics: Cash Position and Activity Update for H1 2017 25
Apr 20, 2017: Cerenis Therapeutics : Cash position and update on clinical developments for Q1 2017 26
Jan 19, 2017: Cerenis: Clinical progress, cash position and revenue for Q4 2016 27
Corporate Communications 28
Jul 31, 2018: Cerenis Announces the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director 28
May 02, 2018: Seasoned Scientific Experts and Strategic Pharmaceutical Industry Veterans Join Cerenis’ Scientific Advisory Board in Oncology 29
Other Significant Developments 31
Jan 25, 2018: CERENIS Therapeutics: Cash position and activity update for Q4 2017 31
Oct 26, 2017: Cerenis Therapeutics: Cash Position and Activity Update for Q3 2017 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cerenis Therapeutics Holding SA, Deals By Therapy Area, 2012 to YTD 2018 8
Cerenis Therapeutics Holding SA, Medical Devices Deals, 2012 to YTD 2018 9
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cerenis Therapeutics Acquires Assets from Lypro Biosciences 11
Cerenis Therapeutics Raises USD4.1 Million in Venture Financing 12
Cerenis Therapeutics Enters into University of North Texas Health Science Center 13
Cerenis Therapeutics to Raise USD1.3 Million in Private Placement of Shares 14
Cerenis Therapeutics Raises USD56.7 Million in IPO 15
Cerenis Therapeutics Acquires Assets from Lypro Biosciences 17
Cerenis Therapeutics Holding SA, Key Competitors 18
Cerenis Therapeutics Holding SA, Key Employees 19
Cerenis Therapeutics Holding SA, Other Locations 20
Cerenis Therapeutics Holding SA, Subsidiaries 20

List of Figures
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cerenis Therapeutics Holding SA, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Cerenis Therapeutics Holding SA (CEREN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Purepoint Uranium Group Inc (PTU):企業の財務・戦略的SWOT分析
    Purepoint Uranium Group Inc (PTU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Fugro GeoServices Ltd:企業の戦略的SWOT分析
    Fugro GeoServices Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Avesthagen Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Avesthagen Ltd (Avesthagen) is a life science company that offers preventive personalized healthcare solutions. The company offers bio-nutrition, bio-agriculture and bio-pharmaceutical products. Its bio-nutrition products include validated bio-actives from Indian medicinal plants for prevent …
  • Platte River Power Authority:企業の発電所・SWOT分析2018
    Platte River Power Authority - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Empresa Electricidad del Peru SA (ELECPBC1):企業の財務・戦略的SWOT分析
    Empresa Electricidad del Peru SA (ELECPBC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Toyota Industries Corp (6201):企業の財務・戦略的SWOT分析
    Toyota Industries Corp (6201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • UGI Corp (UGI):企業の財務・戦略的SWOT分析
    UGI Corp (UGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Keepmoat Ltd:企業の戦略的SWOT分析
    Keepmoat Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • International Business Machines Corporation:企業のM&A・事業提携・投資動向
    International Business Machines Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's International Business Machines Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • ASC Pty Ltd:企業の戦略・SWOT・財務情報
    ASC Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary ASC Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • RainDance Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary RainDance Technologies Inc (RDT) is a developer of genomic tools for non-invasive liquid biopsy applications. The company’s products include RainDrop Plus, a digital PCR system that provides picoliter droplets for multiplex detection of HIV and DNA. It also offers RainDrop Plus digital PCR s …
  • Verbundnetz Gas Aktiengesellschaft:石油・ガス:M&Aディール及び事業提携情報
    Summary Verbundnetz Gas AG (VNG), a subsidiary of EnBW Energie Baden-Wurttemberg AG, is a natural gas company that explores, produces, stores, trades and transports natural gas. The company has natural gas licenses on the Norwegian continental shelf and the Danish North Sea. VNG also offers gas stor …
  • Integracion Energetica Argentina SA:企業の戦略的SWOT分析
    Integracion Energetica Argentina SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • BW Offshore Ltd (BWO):石油・ガス:M&Aディール及び事業提携情報
    Summary BW Offshore Ltd (BW Offshore) is a floating production services provider to the oil and gas industry. The company specializes in the design, development, and operation of oil and gas Floating Production, Storage and Offloading (FPSO) and Floating, Storage and Offloading (FSO) vessels. It off …
  • Medifirst Solutions Inc (MFST):医療機器:M&Aディール及び事業提携情報
    Summary Medifirst Solutions Inc (Medifirst Solutions) is a developer of non-invasive methods and technology for healthcare sector. The company’s flagship product includes the time machine infrared laser TTML-8102000 - 810/830nm, which treats patients suffering from various chronic pain conditions in …
  • The Pep BoysManny, Moe & Jack:企業の戦略・SWOT・財務分析
    The Pep BoysManny, Moe & Jack - Strategy, SWOT and Corporate Finance Report Summary The Pep BoysManny, Moe & Jack - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • NovoCure Ltd (NVCR):企業の財務・戦略的SWOT分析
    NovoCure Ltd (NVCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Union Bank of India:企業の戦略・SWOT・財務情報
    Union Bank of India - Strategy, SWOT and Corporate Finance Report Summary Union Bank of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • MedDay SA:製薬・医療:M&Aディール及び事業提携情報
    Summary MedDay SA (MedDay) is a biotechnology company that develops drugs for nervous system disorders. The company provides clinical and pharmaceutical development in the field of rare inborn errors of metabolism to treat elucidation of metabolism pathways in the brain. Its pipeline products compri …
  • Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆